leisure time -WSS

leisure time

author：explore 2025-09-28 01:36:30 - browse：3

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： STAT Readout Newsletter: Today's biggest biotech updates

hotspot

WSS

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Pharmacists can make shortage drugs, but at what cost?

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

UnitedHealth’s board chair also owns a personal investment firm

STAT Summit: GSK CEO on pharma giant's new direction

Researchers explore possible ties between long Covid, menopause

focus

leisure time

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

FDA struggles to regulate food additives, sometimes for decades

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA struggles to regulate food additives, sometimes for decades

Peter Hotez and the public health issue of online harassment

Morphosys mixed study results for blood cancer drug

ChatGPT in medicine: STAT answers readers' burning questions

Pharmacists can make shortage drugs, but at what cost?

What does generative AI mean for health care? We asked experts

HHS leader on health, climate change and biopharma emissions

focus

Astellas still sees hope in its gene therapy after four deaths

David Sabatini, ex

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Readout LOUD podcast: A CRISPR milestone, biotech mixology

How climate

Studies point to risks of excluding people with obesity from drug trials

leisure time

hotspot

entertainment

hotspot